For the treatment and prevention of tick, flea and mite infestations in dogs. Bravecto® kills adult, and juvenile ticks (larvae and nymphs). Bravecto® can be used as part of a treatment strategy for flea allergy dermatitis (FAD). For the treatment of Demodicosis caused by Demodex spp. and Sarcoptic mange mites. In a controlled trial, treatment with fluralaner resulted in the complete removal of Demodex spp. mites from treated dogs.
For the treatment of Otodectes spp. ear mite infestations.
The flea insecticidal efficacy of Bravecto® (fluralaner) significantly reduces the likelihood of Dipylidium caninum (tapeworm) transmission from fleas to susceptible dogs throughout the 84 days following a single treatment, by controlling fleas on dogs and lowering the flea burden in the dog’s immediate environment.
Bravecto 1000mg Chewable Tablets are an innovative treatment for flea and tick infestations in dogs weighing 20 - 40kg.
Containing an extoparasticide called Fluralaner that works quickly and effectively to kill fleas and ticks for up to 12 weeks in a single dose, Bravecto will also provide effective treatment for demodicosis and sarcoptic mange.
FOR ANIMAL USE ONLY
BRAVECTO® DOSAGE
| Weight (kg) | Tablet size |
| 2,0 – 4,5 | 112,5 mg for miniature dogs |
| > 4,5 – 10 | 250 mg for small dogs |
| > 10 – 20 | 500 mg for medium dogs |
| > 20 – 40 | 1 000 mg for large dogs |
| > 40 – 56 | 1 400 mg for extra-large dogs |
COMPOSITION
Contains fluralaner equivalent to 25 to 56 mg/kg body weight.
Each chewable tablet contains:
Miniature Dogs: 112,5 mg
Small Dogs: 250 mg
Medium Dogs: 500 mg
Large Dogs: 1 000 mg
Extra-Large Dogs: 1 400 mg
Excipients: aspartame, disodium embonate monohydrate, glycerol, liver flavour, Macrogol 3350, magnesium stearate, maize starch, sodium lauryl sulphate, soyabean oil, sucrose.
EFFICACY
Bravecto® was shown to be effective* against fleas and various tick species.
* Efficacy > 90 to 95 %
Bravecto® is indicated for the treatment of the following:
TICKS: (Ixodes ricinus, Ixodes hexagonus, Ixodus scapularis, Dermacentor reticulatus, Dermacentor variabilis, Haemaphysalis elliptica and Rhipicephalus sanguineus.)
Directly after treatment, at least 90 % of ticks on dogs are killed within 8 hours. During the whole treatment interval, at least 90 % of ticks on dogs are killed within 12 hours.
FLEAS: (Ctenocephalides felis)
Directly after treatment, at least 95 % of fleas are killed within 8 hours. During the whole treatment interval, at least 95 % of fleas on dogs are killed within 12 hours.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
Effect on immature stages
Bravecto® kills adult as well as juvenile ticks (larvae, nymphs). Newly emerged fleas on a dog are killed before viable eggs are produced. An in vitro study alsodemonstrated that very low concentrations of fluralaner stops the production of viable eggs by fleas.
Control of flea infestations and flea allergy dermatitis (FAD)
The flea life cycle is broken due to the rapid onset of action and long-lasting efficacy against adult fleas on the animal and the absence of viable egg production. Bravecto® effectively controls environmental flea populations in areas to which the dog has access. Bravecto® can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Mites
A single oral administration of Bravecto® chewable tablets to dogs with Sarcoptes spp. and Otodectes spp.infestations showed a 100 % reduction in live mite counts as well as a complete elimination of live mites 28 days after treatment administration. The treatment resulted in a reduction of skin lesions and increase of hair re-growth.
Single oral administration of Bravecto® chewable tablets is highly effective against generalised demodicosis caused by Demodex spp., with no mites detectable at 56- and 84-days following treatment.
The flea insecticidal efficacy of Bravecto® (fluralaner) significantly reduces the likelihood of Dipylidium caninum (tapeworm) transmission from fleas to susceptible dogs throughout the 84 days following a single treatment, by controlling fleas on dogs and lowering the flea burden in the dog’s immediate environment.
IDENTIFICATION
Light to dark brown chewable tablet with a smooth or slightly rough surface and circular shape. Some marbling, speckles or both may be visible.
PRESENTATION
Packaged in an aluminium foil blister with aluminium foil lid stock in an outer carton.
